Drugs Made In America Acquisition (DMAA) Net Cash Flow (2025)

Drugs Made In America Acquisition's (DMAA) quarterly Net Cash Flow came in at $5420.0 in Q4 2025, up 5261.9% on a QoQ basis from -$105.0 in Q3 2025.

Drugs Made In America Acquisition (DMAA) Net Cash Flow (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 1 years of Net Cash Flow data on file, last reported at $5420.0 in Q4 2025.

Quarterly Net Cash Flow changed N/A year-over-year to $5420.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4786.0 (changed N/A YoY) and the FY2025 annual result came in at $4786.0, up 254.26% from the prior year.
Net Cash Flow advanced to $5420.0 in Q4 2025, from -$105.0 in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of $5420.0 in Q4 2025 to a low of -$428.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Oxley Bridge Acquisition	585.76 Mn	585.76 Mn	-	-162,173.00
2	Launch Two Acquisition	557.86 Mn	557.86 Mn	-	-109,362.00
3	Drugs Made In America Acquisition	506.00 Mn	506.00 Mn	-	-
4	Cantor Equity Partners IV	468.00 Mn	468.00 Mn	-	-
5	GP-Act III Acquisition	401.06 Mn	401.06 Mn	-	-
6	Aldel Financial	397.49 Mn	397.49 Mn	-	-81,520.00
7	Pioneer Acquisition I	390.89 Mn	653.32 Mn	-	-100,073.00
8	Republic Digital Acquisition	389.25 Mn	388.51 Mn	-	-58,765.00
9	Gores Holdings X	385.06 Mn	384.87 Mn	-	-236,785.00
10	Drugs Made In America Acquisition	215.62 Mn	215.62 Mn	-	-

Download Data